Venturi Wealth Management LLC Grows Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

Venturi Wealth Management LLC increased its stake in Amedisys, Inc. (NASDAQ:AMED) by 397.4% during the 4th quarter, HoldingsChannel reports. The firm owned 975 shares of the health services provider’s stock after buying an additional 779 shares during the period. Venturi Wealth Management LLC’s holdings in Amedisys were worth $89,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. lifted its stake in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares during the period. HBW Advisory Services LLC purchased a new stake in Amedisys during the fourth quarter valued at approximately $38,000. Versant Capital Management Inc raised its position in Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after acquiring an additional 183 shares during the period. KBC Group NV purchased a new position in Amedisys during the third quarter valued at $63,000. Finally, Signaturefd LLC grew its stake in shares of Amedisys by 20.9% during the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock valued at $132,000 after acquiring an additional 236 shares during the period. Institutional investors own 94.36% of the company’s stock.

Amedisys Stock Performance

Shares of NASDAQ AMED opened at $90.43 on Monday. The company has a market cap of $2.96 billion, a P/E ratio of 35.88, a P/E/G ratio of 1.80 and a beta of 0.73. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The firm’s fifty day moving average is $90.74 and its two-hundred day moving average is $93.37.

Analysts Set New Price Targets

Separately, Stephens reaffirmed an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a report on Wednesday, February 12th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Amedisys presently has an average rating of “Hold” and an average target price of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.